Washington, DC (PRWEB) March 08, 2012
Nearly all health care payors agree: injectable drugs are a significant cost driver, and with an expanding oncology pipeline, that isn’t likely to change soon. As a result, payors are implementing new strategies to manage these costs, and ICORE’s 2011 Medical Pharmacy & Oncology Trend Report provides the only source for trends and benchmarking statistics for injectables paid under the medical benefit.
On March 20, Michael Waterbury, President of ICORE, will speak about the significant findings in the Report during “Medical Pharmacy the Future of Pharmacy Benefit Management,” a free webinar managed for ICORE Healthcare by Atlantic Information Services Inc. Visit http://aishealth.com/icore-webinar for registration information.
Key findings of the report include:
- Payors are becoming more sophisticated at managing injectables
- Site of service has significant cost implications
- While copays and coinsurance are increasing, payors are looking to strike a balance
- Screenings and genomic testing are being used to increase positive outcomes and manage costs
To compile the 2011 report, ICORE surveyed 60 medical, pharmacy and clinical directors, representing health plans that provide medical and pharmacy benefits for 153 million lives, and evaluated paid claim files for health plans’ medical benefit injectables. This edition also provides a comparison between data from 2011 and 2010, the first year this report was issued.
“For 2011, we’ve been able to add comparisons to last year’s data which has helped to establish solid benchmarks to better track the direction of the industry. The trend report provides a data-driven analysis of how payors are responding to specialty pharmacy challenges,” said Waterbury.
Visit http://aishealth.com/icore-webinar for more details and registration information.